RxDoctor Payments Data

Candice Nipp, NP

Family · Thomaston, GANPI 1699128595

Payments from drug & device makers

$3,386in general payments, 2019–2025

Across 146 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$702
  • Abbott$588
  • Merck$384
  • Novartis$367
  • Pfizer$223
  • E.r. Squibb & Sons, L.L.C.$188
  • plus $934 from 18 others

What the payments were for

  • Travel & lodging$2778%
  • Food & beverage$3,11092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,386 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$23,326
Medicare patients
150
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$170,113
EntrestoSacubitril/Valsartan52$61,164
FarxigaDapagliflozin Propanediol39$40,447
XareltoRivaroxaban14$14,417
Diltiazem 12hr ErDiltiazem Hcl17$2,510
Ranolazine ErRanolazine15$1,400
ClopidogrelClopidogrel Bisulfate151$1,234
Metoprolol Succinate108$907
Valsartan21$819
Atorvastatin Calcium141$754
Hydralazine Hcl53$742
Losartan Potassium100$720
Labetalol Hcl22$635
Carvedilol134$561
Amiodarone Hcl36$533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$170,113176 claims
NovartisEntresto$367$61,16452 claims
AstraZenecaFarxiga$159$40,44739 claims
Johnson & JohnsonXarelto$62$14,41714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Thomaston

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →